23andMe Holding (NASDAQ:ME) Confirms All Potential Buyers Must Comply With Privacy Policy and Applicable Law

23andMe Confirms All Potential Buyers Must Agree to Comply with Privacy Policy and Applicable Law

MOUNTAIN VIEW, Calif., March 23, 2023 /PRNewswire/ -- 23andMe, Inc. (NASDAQ: ME), a leading consumer genetics company, today confirmed that all potential buyers of the company must agree to comply with its privacy policy and applicable law.

In a statement, the company emphasized that it is committed to protecting the privacy and security of its customers' sensitive genetic and health information. As part of the company's commitment to this principle, all potential buyers must agree to adhere to 23andMe's privacy policy, which includes robust measures to safeguard customer data and ensure compliance with relevant laws and regulations.

"We are proud of our legacy of protecting our customers' privacy and security, and we will not compromise on this principle," said Anne Wojcicki, CEO of 23andMe. "We will only work with buyers who share our commitment to respecting and protecting our customers' sensitive information."

The company's privacy policy has been recognized as a benchmark for the industry, and 23andMe has consistently demonstrated its commitment to transparency and accountability in its handling of customer data.

The company's confirmation comes as 23andMe continues to explore strategic options for its future growth and development. The company has been at the forefront of the direct-to-consumer (DTC) genetic testing market, and its innovative approach has disrupted the traditional healthcare industry.

As 23andMe moves forward, it remains committed to its core values of innovation, integrity, and customer trust. The company's dedication to protecting customer privacy and security is a key part of this commitment, and it will continue to prioritize this principle as it explores new opportunities for growth and development.

About 23andMe 23andMe is a leading consumer genetics company dedicated to helping people access and benefit from the power of their own genetic information. Since its founding in 2006, the company has become a pioneer in the field of direct-to-consumer genetic testing, and its innovative approach has disrupted the traditional healthcare industry. With a focus on innovation, integrity, and customer trust, 23andMe is committed to helping people understand their genetic information and use it to improve their health and well-being.